Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked.
The question about Analytical identity of BPC-157 that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
The opening post and I disagree about the size of the effect, not about the direction.
Comparisons between suppliers in this family are more meaningful than usual precisely because the analysis is straightforward. A supplier that cannot produce a clean result on a simple peptide has told you something.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
Two people can read the same figure differently here and both be reasonable.
This follows post #4 rather than contradicting it.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
Offering a way to settle Analytical identity of BPC-157 rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
On identity: a short sequence gives a distinctive mass and a distinctive fragmentation pattern, so mass spectrometry is genuinely informative here. It is also the analysis least often supplied.
If anyone has run this properly I would rather read that than my own guess.
Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.
If anyone can point at the primary source I would be grateful.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
None of the above is medical advice and I am not qualified to give any.
Acetate content can be a substantial fraction of the mass in a short peptide. A vial labelled 5 mg may contain appreciably less than 5 mg of peptide, and the certificate frequently does not say.
Anyone who has looked at this more carefully, please correct the record.
Post #9 and I disagree about the size of the effect, not about the direction.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
That has held every time I have looked, which is not the same as always.
Taking post #12 at face value and following it one step further.
Analytical identity of BPC-157 would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.
The mechanism is plausible, which is not the same as established.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
I am not the right person to answer the follow-up to this.
Worth separating two things that post #14 runs together.
Distinguishing three things in the Analytical identity of BPC-157 discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
This follows post #17 rather than contradicting it.
Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.
I had written a reply contradicting post #17 and deleted it. Here is what survived.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
I looked this up rather than remembered it, which is the right order.
Confirming post #17 from a second method, which matters more than confirming it from a second person.
Where I would push back on the Analytical identity of BPC-157 consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
Post #18 answers the question as asked. The question underneath it is different.
Reading back through the Analytical identity of BPC-157 threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Acetate content can be a substantial fraction of the mass in a short peptide. A vial labelled 5 mg may contain appreciably less than 5 mg of peptide, and the certificate frequently does not say.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
If it helps: the failure mode here is usually boring rather than dramatic.
Post #22 is right about the mechanism and I think understates the practical bit.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
The honest answer is that it depends, and here is what it depends on.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
Speaking for myself and not for anyone else who has posted here.
Comparisons between suppliers in this family are more meaningful than usual precisely because the analysis is straightforward. A supplier that cannot produce a clean result on a simple peptide has told you something.
Worth separating two things that post #24 runs together.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.